Infliximab can reduce mortality from 35 to 14% in critically ill patients with COVID-19: perhaps some potential confounders to consider

Detalles Bibliográficos
Autores principales: Honore, Patrick M., Barreto Gutierrez, Leonel, Kugener, Luc, Redant, Sebastien, Attou, Rachid, Gallerani, Andrea, De Bels, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545152/
https://www.ncbi.nlm.nih.gov/pubmed/33036639
http://dx.doi.org/10.1186/s13054-020-03294-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545152/
https://www.ncbi.nlm.nih.gov/pubmed/33036639
http://dx.doi.org/10.1186/s13054-020-03294-7

Ejemplares similares